$192 Million is the total value of Altium Capital Management LP's 72 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 176.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CBAY | Buy | CYMABAY THERAPEUTICS INC | $11,928,000 | +62.9% | 800,000 | +19.6% | 6.22% | +12.3% |
| New | IMMUNOVANT INCput | $11,517,000 | – | 300,000 | +100.0% | 6.01% | – | |
| IMGN | Buy | IMMUNOGEN INC | $11,505,750 | +25.7% | 725,000 | +49.5% | 6.00% | -13.4% |
| XTNT | Buy | XTANT MED HLDGS INC | $9,827,798 | +69.7% | 8,934,362 | +43.5% | 5.12% | +16.9% |
| Buy | AMYLYX PHARMACEUTICALS INC | $9,790,357 | +145.3% | 534,700 | +189.0% | 5.11% | +69.1% | |
| ADMA | Buy | ADMA BIOLOGICS INC | $9,748,379 | +11.0% | 2,723,011 | +14.4% | 5.08% | -23.5% |
| New | ALIMERA SCIENCES INC | $9,095,735 | – | 2,934,108 | +100.0% | 4.74% | – | |
| New | STRUCTURE THERAPEUTICS INCsponsored ads | $7,815,100 | – | 155,000 | +100.0% | 4.08% | – | |
| CRNX | Buy | CRINETICS PHARMACEUTICALS IN | $7,791,880 | +220.3% | 262,000 | +94.1% | 4.06% | +120.7% |
| New | BIOHAVEN LTD | $7,464,870 | – | 287,000 | +100.0% | 3.89% | – | |
| AXSM | Buy | AXSOME THERAPEUTICS INC | $6,429,880 | +123.7% | 92,000 | +130.0% | 3.35% | +54.1% |
| KRTX | New | KARUNA THERAPEUTICS INC | $5,749,060 | – | 34,000 | +100.0% | 3.00% | – |
| VERA | Buy | VERA THERAPEUTICS INCcl a | $4,574,767 | +137.5% | 333,681 | +178.1% | 2.39% | +63.6% |
| New | SAGIMET BIOSCIENCES INC | $4,251,993 | – | 483,181 | +100.0% | 2.22% | – | |
| OLMA | Buy | OLEMA PHARMACEUTICALS INC | $4,137,250 | +47.8% | 335,000 | +8.1% | 2.16% | +1.8% |
| New | APELLIS PHARMACEUTICALS INCput | $3,804,000 | – | 100,000 | +100.0% | 1.98% | – | |
| SRPT | Buy | SAREPTA THERAPEUTICS INC | $3,551,746 | +10.8% | 29,300 | +4.6% | 1.85% | -23.7% |
| DYN | Buy | DYNE THERAPEUTICS INC | $2,822,400 | +61.9% | 315,000 | +103.2% | 1.47% | +11.5% |
| ACRS | New | ACLARIS THERAPEUTICS INC | $2,760,550 | – | 403,000 | +100.0% | 1.44% | – |
| ABOS | New | ACUMEN PHARMACEUTICALS INC | $2,697,500 | – | 650,000 | +100.0% | 1.41% | – |
| REPL | Buy | REPLIMUNE GROUP INC | $2,652,050 | -12.1% | 155,000 | +19.2% | 1.38% | -39.5% |
| ORIC | New | ORIC PHARMACEUTICALS INC | $2,533,171 | – | 418,706 | +100.0% | 1.32% | – |
| PHAT | Buy | PHATHOM PHARMACEUTICALS INC | $2,281,400 | -23.2% | 220,000 | +6.1% | 1.19% | -47.1% |
| ITCI | New | INTRA-CELLULAR THERAPIES INC | $1,458,520 | – | 28,000 | +100.0% | 0.76% | – |
| New | SOLENO THERAPEUTICS INC | $1,389,360 | – | 47,081 | +100.0% | 0.72% | – | |
| MRSN | New | MERSANA THERAPEUTICS INC | $1,345,103 | – | 1,059,136 | +100.0% | 0.70% | – |
| DMAC | New | DIAMEDICA THERAPEUTICS INC | $1,279,680 | – | 496,000 | +100.0% | 0.67% | – |
| New | ACLARIS THERAPEUTICS INCput | $1,198,750 | – | 175,000 | +100.0% | 0.62% | – | |
| New | ANAVEX LIFE SCIENCES CORPcall | $1,014,595 | – | 154,900 | +100.0% | 0.53% | – | |
| New | ANAVEX LIFE SCIENCES CORPput | $1,014,595 | – | 154,900 | +100.0% | 0.53% | – | |
| New | MARINUS PHARMACEUTICALS INC | $1,006,516 | – | 125,033 | +100.0% | 0.52% | – | |
| GRIL | New | SADOT GROUP INC | $604,819 | – | 865,263 | +100.0% | 0.32% | – |
| New | ARS PHARMACEUTICALS INCput | $378,000 | – | 100,000 | +100.0% | 0.20% | – | |
| New | SNOW LAKE RES LTD | $289,587 | – | 219,384 | +100.0% | 0.15% | – | |
| New | BITCOIN DEPOT INC*w exp 06/30/202 | $9,495 | – | 50,000 | +100.0% | 0.01% | – | |
| New | CONDUIT PHARMACEUTICALS INC*w exp 09/22/202 | $4,500 | – | 100,000 | +100.0% | 0.00% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| FAT BRANDS INC | 12 | Q3 2023 | 0.6% |
| CHINOOK THERAPEUTICS INC | 11 | Q2 2023 | 8.9% |
| BELLUS HEALTH INC NEW | 10 | Q1 2023 | 4.7% |
| XTANT MED HLDGS INC | 10 | Q3 2023 | 5.1% |
| IVERIC BIO INC | 10 | Q1 2023 | 2.3% |
| MYRIAD GENETICS INC | 10 | Q1 2023 | 2.3% |
| HARBOR CUSTOM DEVELOPMENT IN | 10 | Q3 2023 | 0.1% |
| CRINETICS PHARMACEUTICALS IN | 9 | Q3 2023 | 4.1% |
| CTI BIOPHARMA CORP | 9 | Q1 2023 | 2.6% |
| POLISHED COM INC | 9 | Q2 2023 | 3.4% |
View Altium Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Marpai, Inc. | April 26, 2023 | 1,805,327 | 6.2% |
| Astria Therapeutics, Inc. | February 14, 2023 | 1,355,372 | 5.0% |
| HyreCar Inc. | February 14, 2023 | 1,688,120 | 5.6% |
| Muscle Maker, Inc. | February 14, 2023 | 2,888,085 | 5.0% |
| NeuroBo Pharmaceuticals, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| PALISADE BIO, INC.Sold out | February 14, 2023 | 0 | 0.0% |
| 1847 Goedeker Inc. | February 14, 2022 | 6,103,824 | 5.0% |
| BioRestorative Therapies, Inc. | February 14, 2022 | 200,000 | 5.0% |
| BriaCell Therapeutics Corp. | February 14, 2022 | 900,000 | 4.7% |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. | February 14, 2022 | 363,000 | 5.0% |
View Altium Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-05-08 |
| SC 13G | 2024-02-21 |
| SC 13G | 2024-02-20 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
View Altium Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.